OSE Immuno, a prominent entity within the Health Care sector, specifically operates in the Biotechnology industry. The company is listed on the NYSE Euronext Paris, with its financial transactions conducted in Euros (EUR). As of October 7, 2025, OSE Immuno’s close price was recorded at 6.75 EUR. Over the past year, the company’s stock has experienced significant fluctuations, reaching a 52-week high of 11.58 EUR on November 3, 2024, and a 52-week low of 4.42 EUR on April 6, 2025.

The market capitalization of OSE Immuno stands at 158,030,000 EUR, reflecting its valuation in the market. The company’s price-to-earnings (P/E) ratio is currently 4.987, indicating the market’s valuation of the company relative to its earnings. This ratio is a critical metric for investors assessing the company’s financial health and growth potential.

OSE Immuno’s presence in the biotechnology sector underscores its focus on innovative healthcare solutions. The company’s strategic positioning within this industry highlights its commitment to advancing medical technologies and therapies. As a publicly traded entity on the NYSE Euronext Paris, OSE Immuno is subject to rigorous financial reporting and regulatory standards, ensuring transparency and accountability to its investors.

The recent performance of OSE Immuno’s stock, marked by its volatility within the 52-week range, suggests a dynamic market response to various factors influencing the biotechnology sector. Investors and stakeholders closely monitor such metrics to gauge the company’s market performance and strategic direction.

In summary, OSE Immuno remains a key player in the biotechnology industry, with its financial metrics and market activities reflecting its ongoing efforts to innovate and grow within the healthcare sector. The company’s market cap and P/E ratio provide valuable insights into its financial standing and investor sentiment, making it a noteworthy entity for those interested in the biotechnology and healthcare markets.